Latest & greatest articles for venlafaxine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on venlafaxine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on venlafaxine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for venlafaxine

1. Venlafaxine

Venlafaxine Top results for venlafaxine - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for venlafaxine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

2. Desvenlafaxine versus Venlafaxine for the Treatment of Adult Patients with Major Depressive Disorder: A Review of the Comparative Clinical and Cost-Effectiveness

Desvenlafaxine versus Venlafaxine for the Treatment of Adult Patients with Major Depressive Disorder: A Review of the Comparative Clinical and Cost-Effectiveness Desvenlafaxine versus Venlafaxine for the Treatment of Adult Patients with Major Depressive Disorder: A Review of the Comparative Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Desvenlafaxine versus Venlafaxine for the Treatment of Adult Patients with Major Depressive Disorder: A Review of the Comparative (...) Clinical and Cost-Effectiveness Desvenlafaxine versus Venlafaxine for the Treatment of Adult Patients with Major Depressive Disorder: A Review of the Comparative Clinical and Cost-Effectiveness Published on: October 25, 2017 Project Number: RC0921-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of desvenlafaxine versus venlafaxine for the treatment of adult patients with Major Depressive

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

3. Venlafaxine: unjustifiable cardiovascular risks

Venlafaxine: unjustifiable cardiovascular risks Prescrire IN ENGLISH - Spotlight ''Venlafaxine: unjustifiable cardiovascular risks'', 1 April 2016 {1} {1} {1} | | > > > Venlafaxine: unjustifiable cardiovascular risks Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Venlafaxine: unjustifiable cardiovascular risks There is considerable evidence (...) that venlafaxine carries an increased risk of adverse cardiovascular effects and of overdose deaths, compared with most other "selective" serotonin reuptake inhibitors (SSRIs), whereas the efficacy of all SSRIs is similar – and limited. The antidepressants that are on the market appear to be similar in terms of efficacy, but differ with regard to their adverse effects, depending on their mechanism of action. Venlafaxine shares the adverse effects of "selective" serotonin reuptake inhibitors (SSRIs), but is

Prescrire2016

4. Efficacy of Venlafaxine XR for the Treatment of Pain in Patients With Spinal Cord Injury and Major Depression: A Randomized, Controlled Trial

Efficacy of Venlafaxine XR for the Treatment of Pain in Patients With Spinal Cord Injury and Major Depression: A Randomized, Controlled Trial 25527253 2015 03 27 2015 06 01 2015 11 19 1532-821X 96 4 2015 Apr Archives of physical medicine and rehabilitation Arch Phys Med Rehabil Efficacy of venlafaxine XR for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial. 680-9 10.1016/j.apmr.2014.11.024 S0003-9993(14)01306-9 To (1) determine (...) the efficacy of venlafaxine XR for the treatment of pain (secondary aim) in individuals with spinal cord injury (SCI) enrolled in a randomized controlled trial (RCT) on the efficacy of venlafaxine XR for major depressive disorder (MDD) (primary aim); and (2) test the hypothesis that venlafaxine XR would be effective for both neuropathic and nociceptive pain. Multisite, double-blind, randomized (1:1) controlled trial with subjects block randomized and stratified by site, lifetime history of substance abuse

EvidenceUpdates2015

5. Do venlafaxine and gabapentin control hot flashes in women with a history of breast cancer?

Do venlafaxine and gabapentin control hot flashes in women with a history of breast cancer? Do venlafaxine and gabapentin control hot flashes in women with a history of breast cancer? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do venlafaxine and gabapentin control hot flashes in women with a history of breast (...) cancer? View/ Open Date 2012-12 Format Metadata Abstract Venlafaxine reduces hot flashes more than placebo in women with a history of breast cancer; adverse effects include dry mouth and constipation (strength of recommendation [SOR]: B, randomized clinical trials [RCTs] with heterogeneous outcomes). Gabapentin also reduces hot flashes more than placebo (SOR: B, a single RCT); adverse effects include dizziness and somnolence (SOR: C, standard reference). After having tried both medications, women

Clinical Inquiries2014

6. Tricyclic antidepressants, clonidine, venlafaxine, and modafinil for the treatment of attention-deficit/hyperactivity disorder in adults: a review of the clinical evidence

Tricyclic antidepressants, clonidine, venlafaxine, and modafinil for the treatment of attention-deficit/hyperactivity disorder in adults: a review of the clinical evidence Tricyclic antidepressants, clonidine, venlafaxine, and modafinil for the treatment of attention-deficit/hyperactivity disorder in adults: a review of the clinical evidence Tricyclic antidepressants, clonidine, venlafaxine, and modafinil for the treatment of attention-deficit/hyperactivity disorder in adults: a review (...) of the clinical evidence CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Tricyclic antidepressants, clonidine, venlafaxine, and modafinil for the treatment of attention-deficit/hyperactivity disorder in adults: a review of the clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary

Health Technology Assessment (HTA) Database.2014

7. Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments Kosten-nutzen-bewertung von venlafaxin, duloxetin, bupropion und mirtazapin im vergleich zu weiteren verordnungsfähigen medika-mentösen behandlungen [Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments] Kosten-nutzen-bewertung von venlafaxin, duloxetin, bupropion und (...) mirtazapin im vergleich zu weiteren verordnungsfähigen medika-mentösen behandlungen [Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Kosten-nutzen-bewertung von venlafaxin, duloxetin, bupropion

Health Technology Assessment (HTA) Database.2014

8. Venlafaxine

Venlafaxine USE OF VENLAFAXINE IN PREGNANCY 0344 892 0909 USE OF VENLAFAXINE IN PREGNANCY (Date of issue: February 2016 , Version: 1.3 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Venlafaxine is a serotonin and noradrenaline reuptake (...) inhibitor (SNRI) indicated for the treatment of depression. Its mechanism of action is similar to that of selective-serotonin reuptake inhibitors (SSRIs), which have been associated with cardiac malformations in the infant following exposure in pregnancy in some but not all studies. Data from cohort studies on the use of venlafaxine in human pregnancy do not indicate an increased overall risk of congenital malformation. However, a large case-control study reported associations with a number of specific

UK Teratology Information Service2014

11. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder

Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder Nordstrom G, Danchenko N, Despiegel N (...) , Marteau F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study investigated the cost-effectiveness of escitalopram compared with venlafaxine extended release, as first-line treatment for adults with major depressive disorder

NHS Economic Evaluation Database.2013

12. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data

A systematic review of duloxetine and venlafaxine in major depression, including unpublished data A systematic review of duloxetine and venlafaxine in major depression, including unpublished data A systematic review of duloxetine and venlafaxine in major depression, including unpublished data Schueler YB, Koesters M, Wieseler B, Grouven U, Kromp M, Kerekes MF, Kreis J, Kaiser T, Becker T, Weinmann S CRD summary The review concluded that venlafaxine was probably preferred for short-term (...) treatment of major depression compared to duloxetine for efficacy and tolerability and a valid alternative in patients who did not tolerate or respond to selective serotonin reuptake inhibitors and tricyclic/tetracyclic antidepressants. Few studies compared duloxetine and venlafaxine directly. The reliability of the authors’ conclusions is not totally clear. Authors' objectives To evaluate the efficacy and tolerability of two selective serotonin-norepinephrine reuptake inhibitors (SNRIs), duloxetine

DARE.2012

13. Time to relapse after 6 and 12 months` treatment of generalized anxiety disorder with venlafaxine extended release

Time to relapse after 6 and 12 months` treatment of generalized anxiety disorder with venlafaxine extended release 21135327 2010 12 07 2011 01 04 2015 11 19 1538-3636 67 12 2010 Dec Archives of general psychiatry Arch. Gen. Psychiatry Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. 1274-81 10.1001/archgenpsychiatry.2010.170 Generalized anxiety disorder (GAD) is a chronic disorder in need of reliable data to guide long-term (...) treatment. To assess the benefits of 6 and 12 months' treatment of GAD with venlafaxine hydrochloride extended release (XR) in patients who improved after 6 months' open-label venlafaxine XR treatment. After 6 months' open-label venlafaxine XR treatment, improved patients were randomized to venlafaxine XR or placebo for 6 months. All venlafaxine XR patients still in the study at 12 months were randomized to receive venlafaxine XR or placebo, and all placebo patients continued taking placebo for another

EvidenceUpdates2011

14. Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin

Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin Article Text Aetiology Current use of venlafaxine not associated

Evidence-Based Mental Health2010

15. Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder

Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder Article Text

Evidence-Based Mental Health2010

16. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective

Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective Vera-Llonch M, Dukes E, Rejas J, Sofrygin O, Mychaskiw M, Oster G Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared oral pregabalin, an anticonvulsant medication, with venlafaxine extended release, for patients with generalised anxiety disorder. The authors concluded that pregabalin appeared to be cost

NHS Economic Evaluation Database.2010

17. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland

Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland Benedict A, Arellano J, De Cock E, Baird J Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-utility of duloxetine, compared with selective serotonin re-uptake inhibitors (SSRIs), venlafaxine extended release, and mirtazapine, for the treatment of major

NHS Economic Evaluation Database.2010

18. Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK

Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK Lenox-Smith A, Greenstreet L, Burslem K, Knight C Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of venlafaxine versus either generic fluoxetine or generic amitriptyline for the first-line treatment of patients with major depressive disorder. The authors concluded that, despite its relatively high

NHS Economic Evaluation Database.2009

19. Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder

Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder Xie F, Despiegel N, Danchenko N, Hansen K Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of escitalopram versus venlafaxine and versus fluvoxamine in first-line therapy for patients with major depressive disorder. The authors concluded that escitalopram was a cost-effective option in their setting, when compared

NHS Economic Evaluation Database.2009

20. Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis

Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis van den Broek WW, Mulder PG, van Os E, Birkenhager TK, Pluijms E, Bruijn JA CRD summary This review compared the efficacy and tolerability of venlafaxine with tricyclic antidepressants (...) in depressive disorder, concluding that there was no difference in treatment effect between them. Although the findings appear to represent the evidence, uncertainty over the review process and methodology suggest that the authors' conclusions should be interpreted with caution. Authors' objectives To compare the efficacy and tolerability of venlafaxine with tricyclic antidepressants in depressive disorder. Searching PubMed, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled

DARE.2009